SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jayhawk969 who wrote (4267)3/9/2000 7:11:00 PM
From: Thomas M.   of 10280
 
One line of thought that is out there:

If the FTC rules against SEPR, then it will put in to question SEPR's strategy of partnering with the "parent drug" manufacturer. In theory, this relationaship is ideal, because that company can transition over from the old product to the new & improved one more easily than another company rolling out a new product. Of course, in the case of Seldane/Allegra, HMR was too slow. That hurt Allegra and allowed Claritin to achieve market dominance.

Tom
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News